<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01319045</url>
  </required_header>
  <id_info>
    <org_study_id>Iloprost ACHD</org_study_id>
    <nct_id>NCT01319045</nct_id>
  </id_info>
  <brief_title>Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary arterial hypertension (PAH), or high blood pressure in the lungs, is common in
      patients with congenital heart disease. Historically these patients suffered significant
      morbidity and mortality due to a lack of effective therapies. More recently, advanced
      therapies which target the mechanisms underlying the development and progression of PAH have
      been introduced into clinical care. Oral, intravenous, subcutaneous, and inhaled therapies
      are all available for the treatment of PAH. Patients with PAH are first treated with oral
      agents (including sildenafil and bosentan). However, if these agents fail to achieve the
      desired effect for the patient, intravenous or inhaled therapies may be initiated.
      Combination therapy with multiple agents is common in routine clinical care. However, the
      most efficacious therapeutic regimen has yet to be delineated. The present study seeks to
      evaluate the efficacy of one specific regimen: iloprost, an inhaled prostacyclin derivative,
      used in combination with oral therapy (sildenafil and/or bosentan). Iloprost has been
      approved by the FDA for use in this patient population. Adults with PAH already receiving
      oral therapy will be invited to participate in this study. Iloprost will be added to their
      current therapeutic regimen for a period of three months, with pre- and post-treatment
      assessments. These will include a cardiopulmonary exercise test, BNP (a blood test), six
      minute walking distance, and a quality of life questionnaire.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    enrollment was too slow
  </why_stopped>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>3 months</time_frame>
    <description>Number of Participants with adverse events, specifically mortality and heart failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exercise Capacity</measure>
    <time_frame>3 months</time_frame>
    <description>Change in exercise duration (modified Bruce protocol), maximal oxygen consumption (VO2 max), and/or VE/VCO2 ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Brain Natriuretic Peptide (BNP)</measure>
    <time_frame>3 months</time_frame>
    <description>Change in serum BNP level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>3 months</time_frame>
    <description>Change in quality of life as assessed by SF-36 QOL</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <condition>Congenital Heart Disease</condition>
  <condition>Eisenmenger's Syndrome</condition>
  <arm_group>
    <arm_group_label>Iloprost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered iloprost at 5 mcg/dose x 6 doses daily for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iloprost</intervention_name>
    <description>Aerosolized iloprost, 5 mcg/dose x 6 doses daily for 3 months</description>
    <arm_group_label>Iloprost</arm_group_label>
    <other_name>Ventavis, prostacyclin analogue</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than or equal to 18 years old

          -  Congenital heart disease with pulmonary arterial hypertension and cyanosis (resting
             oxygen saturation &lt; 90% on room air)

          -  Stable on oral therapy (PDE5 inhibitor and/or endothelin blockade) for at least three
             months

        Exclusion Criteria:

          -  Age &lt; 18 years old

          -  Current intravenous or subcutaneous prostacyclin therapy

          -  Resting Systemic Hypotension (Systolic blood pressure &lt; 85 mmHg)

          -  Women who are pregnant or may become pregnant (unwilling to utilize effective
             contraception), as well as nursing mothers

          -  Inability to ambulate

          -  Planned surgical procedure during the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jamil A Aboulhosn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ahmanson / UCLA Adult Congenital Heart Disease Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Beghetti M, Tissot C. Pulmonary arterial hypertension in congenital heart diseases. Semin Respir Crit Care Med. 2009 Aug;30(4):421-8. doi: 10.1055/s-0029-1233311. Epub 2009 Jul 24. Review.</citation>
    <PMID>19634081</PMID>
  </reference>
  <reference>
    <citation>Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):13S-24S. Review.</citation>
    <PMID>15194174</PMID>
  </reference>
  <reference>
    <citation>Niwa K, Perloff JK, Kaplan S, Child JS, Miner PD. Eisenmenger syndrome in adults: ventricular septal defect, truncus arteriosus, univentricular heart. J Am Coll Cardiol. 1999 Jul;34(1):223-32.</citation>
    <PMID>10400015</PMID>
  </reference>
  <reference>
    <citation>Daliento L, Somerville J, Presbitero P, Menti L, Brach-Prever S, Rizzoli G, Stone S. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J. 1998 Dec;19(12):1845-55.</citation>
    <PMID>9886728</PMID>
  </reference>
  <reference>
    <citation>Christman BW. Lipid mediator dysregulation in primary pulmonary hypertension. Chest. 1998 Sep;114(3 Suppl):205S-207S. Review.</citation>
    <PMID>9741570</PMID>
  </reference>
  <reference>
    <citation>Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jöbsis MM, Blackburn SD, Shortino D, Crow JW; Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996 Feb 1;334(5):296-301.</citation>
    <PMID>8532025</PMID>
  </reference>
  <reference>
    <citation>Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, Jöbsis MM, Loyd JE, Murali S, Frost A, Girgis R, Bourge RC, Ralph DD, Elliott CG, Hill NS, Langleben D, Schilz RJ, McLaughlin VV, Robbins IM, Groves BM, Shapiro S, Medsger TA Jr. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000 Mar 21;132(6):425-34.</citation>
    <PMID>10733441</PMID>
  </reference>
  <reference>
    <citation>Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ; Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002 Mar 15;165(6):800-4.</citation>
    <PMID>11897647</PMID>
  </reference>
  <reference>
    <citation>Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W; Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002 Aug 1;347(5):322-9.</citation>
    <PMID>12151469</PMID>
  </reference>
  <reference>
    <citation>McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, Badesch DB, Barst RJ, Hsu HH, Rubin LJ. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006 Dec 1;174(11):1257-63. Epub 2006 Aug 31.</citation>
    <PMID>16946127</PMID>
  </reference>
  <reference>
    <citation>Krug S, Sablotzki A, Hammerschmidt S, Wirtz H, Seyfarth HJ. Inhaled iloprost for the control of pulmonary hypertension. Vasc Health Risk Manag. 2009;5(1):465-74. Review.</citation>
    <PMID>19475782</PMID>
  </reference>
  <reference>
    <citation>Hallioglu O, Dilber E, Celiker A. Comparison of acute hemodynamic effects of aerosolized and intravenous iloprost in secondary pulmonary hypertension in children with congenital heart disease. Am J Cardiol. 2003 Oct 15;92(8):1007-9.</citation>
    <PMID>14556887</PMID>
  </reference>
  <reference>
    <citation>Limsuwan A, Khosithseth A, Wanichkul S, Khowsathit P. Aerosolized iloprost for pulmonary vasoreactivity testing in children with long-standing pulmonary hypertension related to congenital heart disease. Catheter Cardiovasc Interv. 2009 Jan 1;73(1):98-104. doi: 10.1002/ccd.21793.</citation>
    <PMID>19089967</PMID>
  </reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2011</study_first_submitted>
  <study_first_submitted_qc>March 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2011</study_first_posted>
  <results_first_submitted>December 3, 2014</results_first_submitted>
  <results_first_submitted_qc>December 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 29, 2014</results_first_posted>
  <last_update_submitted>January 13, 2015</last_update_submitted>
  <last_update_submitted_qc>January 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Jamil Aboulhosn</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Pulmonary Arterial Hypertension</keyword>
  <keyword>Congenital Heart Disease</keyword>
  <keyword>Eisenmenger's Syndrome</keyword>
  <keyword>Prostacyclin</keyword>
  <keyword>Iloprost</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Eisenmenger Complex</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iloprost</mesh_term>
    <mesh_term>Epoprostenol</mesh_term>
    <mesh_term>Tezosentan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Iloprost</title>
          <description>Participants will be administered iloprost at 5 mcg/dose x 6 doses daily for 3 months.
Iloprost: Aerosolized iloprost, 5 mcg/dose x 6 doses daily for 3 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3">Study was discontinued due to low enrollment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Iloprost</title>
          <description>Participants will be administered iloprost at 5 mcg/dose x 6 doses daily for 3 months.
Iloprost: Aerosolized iloprost, 5 mcg/dose x 6 doses daily for 3 months</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability</title>
        <description>Number of Participants with adverse events, specifically mortality and heart failure.</description>
        <time_frame>3 months</time_frame>
        <population>Number of adverse events.</population>
        <group_list>
          <group group_id="O1">
            <title>Iloprost</title>
            <description>Participants will be administered iloprost at 5 mcg/dose x 6 doses daily for 3 months.
Iloprost: Aerosolized iloprost, 5 mcg/dose x 6 doses daily for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability</title>
          <description>Number of Participants with adverse events, specifically mortality and heart failure.</description>
          <population>Number of adverse events.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exercise Capacity</title>
        <description>Change in exercise duration (modified Bruce protocol), maximal oxygen consumption (VO2 max), and/or VE/VCO2 ratio.</description>
        <time_frame>3 months</time_frame>
        <population>unable to analyze because study was terminated prematurely and therefore follow up assessments were not obtained</population>
        <group_list>
          <group group_id="O1">
            <title>Iloprost</title>
            <description>Participants will be administered iloprost at 5 mcg/dose x 6 doses daily for 3 months.
Iloprost: Aerosolized iloprost, 5 mcg/dose x 6 doses daily for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Exercise Capacity</title>
          <description>Change in exercise duration (modified Bruce protocol), maximal oxygen consumption (VO2 max), and/or VE/VCO2 ratio.</description>
          <population>unable to analyze because study was terminated prematurely and therefore follow up assessments were not obtained</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Brain Natriuretic Peptide (BNP)</title>
        <description>Change in serum BNP level</description>
        <time_frame>3 months</time_frame>
        <population>unable to analyze because study was terminated prematurely and therefore follow up assessments were not obtained</population>
        <group_list>
          <group group_id="O1">
            <title>Iloprost</title>
            <description>Participants will be administered iloprost at 5 mcg/dose x 6 doses daily for 3 months.
Iloprost: Aerosolized iloprost, 5 mcg/dose x 6 doses daily for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Brain Natriuretic Peptide (BNP)</title>
          <description>Change in serum BNP level</description>
          <population>unable to analyze because study was terminated prematurely and therefore follow up assessments were not obtained</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life</title>
        <description>Change in quality of life as assessed by SF-36 QOL</description>
        <time_frame>3 months</time_frame>
        <population>unable to analyze because study was terminated prematurely and therefore follow up assessments were not obtained</population>
        <group_list>
          <group group_id="O1">
            <title>Iloprost</title>
            <description>Participants will be administered iloprost at 5 mcg/dose x 6 doses daily for 3 months.
Iloprost: Aerosolized iloprost, 5 mcg/dose x 6 doses daily for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life</title>
          <description>Change in quality of life as assessed by SF-36 QOL</description>
          <population>unable to analyze because study was terminated prematurely and therefore follow up assessments were not obtained</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Iloprost</title>
          <description>Participants will be administered iloprost at 5 mcg/dose x 6 doses daily for 3 months.
Iloprost: Aerosolized iloprost, 5 mcg/dose x 6 doses daily for 3 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Enrollment was too slow. The trial was discontinued.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jamil Aboulhosn</name_or_title>
      <organization>UCLA</organization>
      <phone>310-825-5950</phone>
      <email>jaboulhosn@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

